Vol. 34 No. 1 (2017)
Original Article

Factores asociados a nefrotoxicidad por polimixina B en un hospital universitario de Neiva, Colombia. 2011-2015

PDF (Español (España))
  • Johanna Osorio,
  • Jackeline Barreto,
  • Claudia F. Samboni,
  • Lina A. Cándelo,
  • Luis C. Álvarez,
  • Susana Benavidez,
  • Roso P. Téllez,
  • Dagoberto Santofimio,
  • Jorge A. Ramos,
  • Carlos A. Gomez

Published 2017-03-31

Keywords

How to Cite

1.
Osorio J, Barreto J, Samboni CF, Cándelo LA, Álvarez LC, Benavidez S, Téllez RP, Santofimio D, Ramos JA, Gomez CA. Factores asociados a nefrotoxicidad por polimixina B en un hospital universitario de Neiva, Colombia. 2011-2015. Rev. Chilena. Infectol. [Internet]. 2017 Mar. 31 [cited 2025 Nov. 26];34(1). Available from: https://revinf.cl/index.php/revinf/article/view/1

Copyright (c) 2017 Johanna Osorio, Jackeline Barreto, Claudia F. Samboni, Lina A. Cándelo, Luis C. Álvarez, Susana Benavidez, Roso P. Téllez, Dagoberto Santofimio, Jorge A. Ramos, Carlos A. Gomez

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Abstract

Background: The rise of infections caused by multidrug-resistant Gram negative bacilli (MDR-GNB), added to paucity of newer therapy, have led to increase polymyxin B use, despite adverse renal toxicity profile.Aim: To determine the incidence and risk factors associated to acute kidney injury (AKI) and polymyxin B use, in patients with infections caused by MDR-GNB.

Methods: A retrospective cohort, with a nested case-control study of adults who received polymyxin B for more than 48 hours at a tertiary university hospital in Colombia (2011-2015) was performed. AKI was definedby AKIN criteria. Results: Of 139 patients included in our study, 102 were male with median age of 49 years (IQR:28-64). Sixty-one patients (44%) developed AKI. Independent risk factors for development of AKI included: total polymyxin B daily dose (OR = 2.19, 95% CI, 1.04-4.64); length of stay at ICU (OR = 1.03, 95% CI, 1.00-1.06); nosocomial infection (OR = 6.43, 95% CI, 2.12, -19.47); and vasopressor use (OR = 5.38, 95% CI, 2.40-12.07). Mortality was higher among AKI-patients (58.6%) compared with non-AKI patients (25.6%) (p = 0.001).

Conclusion: In this study, the rate of AKI associated to polymyxin B use was greater than reported in studies from last decade, and associated with increased mortality. AKI associated to polymyxin B use is likely multifactorial and aggravated by the critically ill state of patients sufferingnosocomial infections caused by mdr-gnb.

PDF (Español (España))